Clik here to view.
Prolific Machinesがトップクラスのプラネタリーヘルス投資家から4200万ドルを調達し、生物学組立ラインを構築へ
サンフランシスコ （ビジネスワイヤ） — 次世代バイオテクノロジー企業のProlific...
View ArticleClik here to view.
CORRECTING and REPLACING SunLike Lighting, With Proven Effectiveness of...
ANSAN, South Korea Please replace the release dated August 29, 2022, with the following corrected version due to multiple revisions. This press release features multimedia. View the full release...
View ArticleClik here to view.
Clik here to view.
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology...
View ArticleClik here to view.
Hyperice推出全新Venom Go和Venom 2，提供热疗解决方案
加州尔湾 (美国商业资讯)–全球高性能健康品牌Hyperice今天推出了两款热疗类新产品：Venom Go和Venom 2，同时还发布了可通过最快、最稳定和最均匀的热量分布来缓解酸痛、肌肉僵硬并促进健康的HyperHeat™技术。Venom Go进一步提升了Venom系列的功能，能够在更多部位提供局部热疗和振动治疗，如颈部、肩部、上背、下背、小腿和前臂。Venom...
View ArticleClik here to view.
Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds...
BOSTON Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock...
View ArticleClik here to view.
バイオサイトジェンがTCRミミック抗体を利用した細胞療法の開発に向けたファインイミューンとの協業を発表
中国・北京 & 広州 （ビジネスワイヤ）– バイオサイトジェン・ファーマシューティカルズ（北京）（以下「バイオサイトジェン」、HKEX:...
View ArticleClik here to view.
ハイパーアイスがまったく新しいベノム・ゴーとベノム2を投入して温熱製品を強化
米カリフォルニア州アーバイン （ビジネスワイヤ） — 世界的なハイパフォーマンス・ウェルネス・ブランドのハイパーアイスは本日、温熱療法カテゴリーの2つの新製品であるベノム・ゴーおよびベノム2（Venom Go、Venom...
View ArticleClik here to view.
Multi-Center, Multi-Society Study of Impella-supported Patients with...
BOSTON Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for...
View ArticleClik here to view.
Blood Cancer Discovery Publication Further Validates Exscientia’s AI...
VIENNA & OXFORD, England Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Blood Cancer...
View ArticleClik here to view.
ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of...
SAN DIEGO & SINGAPORE ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics today announced that it has raised...
View ArticleClik here to view.
Prolific Machines从顶级的星球健康投资人筹集了4,200万美元，用于建立生物学生产线
旧金山 (美国商业资讯)–新一代生物技术公司Prolific Machines今天走出隐身模式，宣布其种子轮和A轮融资实现大幅超额认购。两轮融资均由该领域一流的风险投资人领投。种子轮融资由人造肉的首位投资人、梅菲尔德风险投资公司(Mayfield)的Arvind Gupta领投。A轮融资由比尔·盖茨创立的Breakthrough Energy...
View ArticleClik here to view.
InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that the Company has successfully got listed on the...
View ArticleClik here to view.
NTT Research Formulates System to Optimize Drug Infusion for Acute Heart Failure
SUNNYVALE, Calif. NTT Research, Inc., a division of NTT (TYO:9432), today announced that its Medical & Health Informatics (MEI) Lab has delivered a paper proposing a system design for optimizing...
View ArticleClik here to view.
《血癌发现》论文进一步证实，Exscientia的人工智能精准医疗平台可改善患者各项转归指标
维也纳和英格兰牛津 (美国商业资讯)–Exscientia (Nasdaq: EXAI)、苏黎世联邦理工学院、维也纳医科大学和分子医学中心(Center for Molecular Medicine, CeMM)今天宣布，美国癌症研究学会期刊《血癌发现》(Blood Cancer Discovery)新发表了Berend...
View ArticleClik here to view.
CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the...
SHANGHAI CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces...
View ArticleClik here to view.
BostonGene Showcases Lifesaving Cancer Diagnostic and Treatment...
WALTHAM, Mass. BostonGene announced today that it will participate in the 81st Annual Meeting of the Japanese Cancer Association. The event, to be held at Pacific Convention Plaza Yokohama from...
View ArticleClik here to view.
Impella患者を対象とした大規模多施設共同研究が、急性心筋梗塞に伴う心原性ショック患者の30日生存率が81%であることを示す
ボストン （ビジネスワイヤ） –日本における109か所の医療機関で治療を受けたImpellaによる循環補助を受けた患者（n=1,344）を対象とした3年間の医師主導研究の結果、急性心筋梗塞に伴う心原性ショック（AMICS）患者の30日生存率が81%であることが明らかになりました。本試験は、2020年の中間解析のアップデートであり、ボストンで開催されている2022 Transcatheter...
View ArticleClik here to view.
Tsing Hua University Hospital Preparatory Office Officially Opens in Taoyuan
HSINCHU, Taiwan On August 20, the Tsing Hua University Hospital Preparatory Office was officially opened in the Xinkong Building at the Taoyuan Metro Corporation’s Qingpu Depot, which is only one...
View ArticleClik here to view.
Penumbra and Asahi Intecc Partner With Goal of Introducing Indigo™ System...
ALAMEDA, Calif. Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, and Asahi Intecc Co., a leading Japanese medical device manufacturer, announced that they...
View Article